Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,924 recruiting studies in this area right now.
By phase
- Not applicable2,025
- Phase 21,074
- Phase 1791
- Phase 1/Phase 2480
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama157
- Maryland152
- Arizona126
- Florida104
- Massachusetts104
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,924 total
- NCT06993675RecruitingPhase 2
T-cell therapy for MRD in newly diagnosed myeloma patients after transplant
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
New Haven, ConnecticutAges 18 years+ - NCT07000747Recruiting
Dengue and sickle cell disease study
This study looks at how severe dengue fever affects people with sickle cell disease. It aims to understand why some people with sickle cell get very sick from dengue and how their cells react.
Pointe-à-PitreAges 6–25 - NCT06994169Recruiting
Glofitamab treatment study for relapsed DLBCL
This study looks at how well glofitamab works in real-world patients with a type of lymphoma that has come back or not responded to treatment. It includes adults who have already received obinutuzumab and at least one dose of glofitamab in a special access program.
ArgenteuilAges 18 years+ - NCT07001540RecruitingPhase 2
Targeted drug combo for relapsed DLBCL
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07001384RecruitingPhase 1
Alectinib and Duvelisib for ALK-positive anaplastic large cell lymphoma
This trial tests two oral targeted drugs—alectinib and duvelisib—for people whose ALK-positive anaplastic large cell lymphoma has come back or not responded after at least one prior chemotherapy. The goal is to see if this combination can help control the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06997081RecruitingPhase 2
ERd combination for newly diagnosed multiple myeloma
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Miami, FloridaAges 18 years+ - NCT07002216RecruitingPhase 2
BrECADD therapy for stage 2B to stage 4 Hodgkin lymphoma
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
Miami, FloridaAges 18–60 - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65 - NCT07003100Recruiting
Studying mogamulizumab rash in mycosis fungoides or sezary syndrome
This study looks at a common skin rash caused by the drug mogamulizumab in patients with certain types of lymphoma. It aims to learn more about the rash and how to manage it, so your experience can help future patients.
Duarte, CaliforniaAges 18 years+ - NCT06802055RecruitingPhase 2
Sirolimus with or without cyclosporin for aplastic anemia
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06985576Enrolling by invitation
Long-term safety follow-up for GF-CART01
This study is a long-term follow-up for people who have already received the GF-CART01 treatment in a previous study. It checks how safe the treatment stays over time and how long the effects last.
TaipeiAges Any age - NCT06987058Enrolling by invitationPhase 2
Continued RVU120 treatment study for current participants
This trial is for people who are already in a RVU120 study and have been receiving the drug for at least 5 cycles. It allows you to keep getting RVU120 if you are benefiting from it and don't have other treatment options.
NiceAges 18 years+ - NCT06988488RecruitingPhase 1/Phase 2
Study of mezigdomide plus elranatamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06987916RecruitingPhase 1/Phase 2
Testing new immune cell therapy for B-cell lymphoma
This trial tests a new immune cell treatment (called U01 or ssCART-19) for people with B-cell lymphoma that has come back or not responded to other treatments. It aims to see if the therapy is safe and effective.
Shanghai, Shanghai MunicipalityAges 2–75 - NCT06984536RecruitingPhase 2
Lowered immune drug plus mini transplant method for preventing graft vs host disease
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
BeijingAges 12–65 - NCT06986174RecruitingPhase 2
Pacritinib for relapsed or refractory Waldenström macroglobulinemia
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
Boston, MassachusettsAges 18 years+ - NCT06988020Recruiting
Using MRI to find bone lesions in multiple myeloma
This study tests a new way to make MRI scans look like CT scans to find bone damage from multiple myeloma. You may join if you have just been diagnosed or if your disease came back after strong treatments, and you need bone imaging for staging.
BrusselsAges 18 years+ - NCT06992076Recruiting
Hemophilia patients' experience with marstacimab treatment
This registry study follows people with hemophilia A or B who are taking marstacimab as their regular preventive treatment. It aims to understand how the medicine works in real life and how patients feel during treatment.
Xiamen, FujianAges 12 years+ - NCT06984146RecruitingPhase 2
Nivo40-AVD for advanced Hodgkin lymphoma
This trial tests a combination of nivolumab and chemotherapy (AVD) for people newly diagnosed with advanced classic Hodgkin lymphoma. The goal is to see if adding nivolumab improves treatment outcomes.
MoscowAges 18 years+ - NCT06990321RecruitingPhase 3
Cytarabine and venetoclax for older adults with AML
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
Changchun, JilinAges 60–75 - NCT06985485RecruitingPhase 2
Immunotherapy for older or frail B-ALL patients
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
Suzhou, JiangsuAges 15 years+ - NCT06988059RecruitingEarly Phase 1
Car T-cell therapy for plasma cell leukemia
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06989099RecruitingPhase 2
Preventing lymphedema with immediate lymphatic reconstruction
This study tests if performing immediate lymphatic reconstruction during lymph node removal can prevent lymphedema (arm swelling) in women with inflammatory breast cancer. If you qualify, the procedure may help lower your risk of long-term swelling.
Houston, TexasAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,924 recruiting hematology studies from the U.S. registry right now, out of 7,354 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.